Current Oncology Reports

, 13:361

Upfront Therapy of Acute Myeloid Leukemia


  • Jenna VanLiere Canzoniero
    • Department of Internal MedicineUniversity of Maryland Medical Center
  • Bhavana Bhatnagar
    • Department of Internal Medicine, Division of Hematology/OncologyUniversity of Maryland Medical Center
  • Maria R. Baer
    • University of Maryland Marlene and Stewart Greenebaum Cancer Center
    • University of Maryland Marlene and Stewart Greenebaum Cancer Center

DOI: 10.1007/s11912-011-0184-x

Cite this article as:
Canzoniero, J.V., Bhatnagar, B., Baer, M.R. et al. Curr Oncol Rep (2011) 13: 361. doi:10.1007/s11912-011-0184-x


Acute myeloid leukemia is a clinically and biologically heterogeneous disease. Standard induction chemotherapy, consisting of cytarabine and an anthracycline, has not changed substantially over several decades, and outcomes remain suboptimal, particularly in older patients. Many genetic and molecular changes have been identified that guide selection of post-remission therapy and for which targeted therapies are beginning to be developed and tested. These research efforts are resulting in gradual improvement in outcomes. We will review here recent advances in induction chemotherapy, including anthracycline dose intensification in younger patients, treatment selection and use of novel agents in upfront therapy for older patients, and risk-adapted post-remission therapy.


Acute myeloid leukemiaChemotherapyNovel drugsTransplant

Copyright information

© Springer Science+Business Media, LLC 2011